RxDoctor Payments Data

Daniel Gruber, MD

Urogynecology and Reconstructive Pelvic Surgery · Bethesda, MDNPI 1841225133

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $61,800 of the $90,837 with a category attached, or 68.0%. AbbVie accounts for 78.2% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $24,873, more than ten times the $481 reported in 2019.

$90,837in general payments, 2019–2025

Across 212 payments — averaging $428.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$71K
  • Pacira Pharmaceuticals Incorporated$8K
  • Caldera Medical, Inc$7K
  • Axonics, Inc.$2K
  • Boston Scientific$2K
  • Coloplast$1K
  • plus $572 from 9 others

What the payments were for

  • Consulting fees$11,47513%
  • Speaking & faculty fees$61,80068%
  • Travel & lodging$10,17111%
  • Food & beverage$7,3368%
  • Gifts$540%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$181,665
Medicare patients
268
Services billed
4,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron79$48,818
Estradiol146$9,585
Methenamine Hippurate14$1,816
NitrofurantoinNitrofurantoin Macrocrystal14$207
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$108
Oxycodone Hcl13$24

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →